Launching a novel drug into a new market is tough. UCB’s Kimberly Moran, talked to In Vivo about how being both patient and digital first gives the company a competitive commercial advantage in an increasingly growing market.

BioDirection Inc. is poised to launch what it says is the first objective point-of-care test for diagnosing concussion and other traumatic brain injury. Based on proprietary nanotechnology, the company’s Tbit device detects molecular levels of two crucial brain biomarkers that are released into the bloodstream immediately after a brain injury, from just a single drop of blood in less than two minutes.

BioDirection Inc. is poised to launch what it says is the first objective point-of-care test for diagnosing concussion and other traumatic brain injuries. Based on proprietary nanotechnology, the company’s Tbit device detects molecular levels of two crucial brain biomarkers that are released into the bloodstream immediately after a brain injury, from just a single drop of blood in less than two minutes.

Biogen brings Tysabri fully in-house by using off-shore cash to compensate Irish partner Elan. Plus, the week in biopharma deal-making.